Printer Friendly

Halozyme Therapeutics reports Q3 2019 financial results.

M2 PHARMA-November 13, 2019-Halozyme Therapeutics reports Q3 2019 financial results

(C)2019 M2 COMMUNICATIONS

Halozyme Therapeutics Inc (NASDAQ: HALO), a biotechnology company focused on novel biological and drug delivery approaches, announced yesterday its financial results for the third quarter of 2019.

The company reported revenue for the third quarter of 2019 at USD46.2m or USD0.17 per share, compared to USD25.6m in the same period in 2018.

The firm posted net loss for the third quarter of 2019 at USD25m compared to a net loss of USD27.9m or USD0.19 per share for the year-ago period.

'We have transitioned our strategy to focus solely on our high-growth, high-margin ENHANZE drug delivery technology,' said Dr. Helen Torley, president and chief executive officer. 'With profitability anticipated in the second quarter of 2020 and a long runway for growth with ENHANZE, we are in a strong position to build value and return capital to investors.'

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Financial report
Date:Nov 13, 2019
Words:166
Previous Article:Kindred Biosciences reports nine months ended 30 September 2019 financial results.
Next Article:Sobi announces completion of acquisition of Dova Pharmaceuticals at USD27.5 per share.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters